UBS Group’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-2,369
| Closed | -$8.06K | – | 11145 |
|
|
2025
Q2 | $8.06K | Buy |
2,369
+32
| +1% | +$106 | ﹤0.01% | 8982 |
|
|
2025
Q1 | $6.59K | Buy |
2,337
+1,651
| +241% | +$4.87K | ﹤0.01% | 8892 |
|
|
2024
Q4 | $1.9K | Buy |
+686
| New | +$2.24K | ﹤0.01% | 9146 |
|
|
2024
Q3 | – | Sell |
-183
| Closed | -$809 | – | 10215 |
|
|
2024
Q2 | $809 | Buy |
+183
| New | +$1.4K | ﹤0.01% | 8770 |
|
|
2024
Q1 | – | Sell |
-26
| Closed | -$193 | – | 10140 |
|
|
2023
Q4 | $193 | Buy |
26
+8
| +44% | +$59 | ﹤0.01% | 8823 |
|
|
2023
Q3 | $180 | Buy |
+18
| New | +$200 | ﹤0.01% | 8739 |
|
|
2023
Q1 | – | Sell |
-88
| Closed | -$1.12K | – | 10540 |
|
|
2022
Q4 | $1.12K | Buy |
+88
| New | +$1.3K | ﹤0.01% | 9951 |
|
|
2022
Q3 | – | Sell |
-52
| Closed | -$1K | – | 11040 |
|
|
2022
Q2 | $1K | Sell |
52
-37
| -42% | -$926 | ﹤0.01% | 9993 |
|
|
2022
Q1 | $3K | Sell |
89
-448
| -83% | -$16.1K | ﹤0.01% | 9501 |
|
|
2021
Q4 | $19K | Buy |
+537
| New | +$28.3K | ﹤0.01% | 7920 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 10180 |
|
|
2021
Q2 | – | Sell |
-69
| Closed | -$8K | – | 9905 |
|
|
2021
Q1 | $8K | Sell |
69
-484
| -88% | -$53.7K | ﹤0.01% | 8101 |
|
|
2020
Q4 | $24K | Buy |
+553
| New | +$20.5K | ﹤0.01% | 6817 |
|
|
2020
Q2 | – | Sell |
-19
| Closed | -$1K | – | 8430 |
|
|
2020
Q1 | $1K | Hold |
19
| – | – | ﹤0.01% | 7818 |
|
|
2019
Q4 | $2K | Buy |
+19
| New | +$1.77K | ﹤0.01% | 7857 |
|
|
2019
Q3 | – | Sell |
-5
| Closed | -$1K | – | 8314 |
|
|
2019
Q2 | $1K | Sell |
5
-30
| -86% | -$10.6K | ﹤0.01% | 7748 |
|
|
2019
Q1 | $16K | Buy |
35
+25
| +250% | +$9.7K | ﹤0.01% | 6508 |
|
|
2018
Q4 | $3K | Sell |
10
-127
| -93% | -$30.4K | ﹤0.01% | 7743 |
|
|
2018
Q3 | $24K | Buy |
137
+131
| +2,183% | +$24K | ﹤0.01% | 6703 |
|
|
2018
Q2 | $1K | Buy |
+6
| New | +$1.11K | ﹤0.01% | 7852 |
|
|
2017
Q2 | – | Sell |
-31
| Closed | -$9K | – | 8043 |
|
|
2017
Q1 | $9K | Buy |
+31
| New | +$9.12K | ﹤0.01% | 6691 |
|
|
2016
Q4 | – | Sell |
-22
| Closed | -$7K | – | 8092 |
|
|
2016
Q3 | $7K | Buy |
+22
| New | +$7.71K | ﹤0.01% | 7002 |
|
|
2016
Q1 | – | Sell |
-45
| Closed | -$20K | – | 8282 |
|
|
2015
Q4 | $20K | Buy |
45
+40
| +800% | +$25.1K | ﹤0.01% | 6768 |
|
|
2015
Q3 | $4K | Buy |
+5
| New | +$7.28K | ﹤0.01% | 7852 |
|
|
2015
Q1 | – | Sell |
-4
| Closed | -$25K | – | 9475 |
|
|
2014
Q4 | $25K | Buy |
+4
| New | +$33.6K | ﹤0.01% | 7332 |
|
Other funds holding CSCI
UBS Group's CSCI Position: Q3 2025 in Review
UBS Group sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q3 2025, closing a stake of 2,369 shares — an estimated $8.06K sold.
UBS Group first reported a position in CSCI in Q4 2014 and held it in 24 quarters. The position peaked at $25K in Q4 2014. 2 funds tracked by Wall St. Rank hold CSCI as of Q3 2025.
- UBS Group reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q3 2025 after selling out during the quarter.
- UBS Group sold 2,369 COSCIENS Biopharma Inc. Common Stock shares in Q3 2025, an estimated $8.06K.
- UBS Group first reported a position in COSCIENS Biopharma Inc. Common Stock in Q4 2014 and held it in 24 quarters.
- UBS Group's COSCIENS Biopharma Inc. Common Stock position peaked at $25K in Q4 2014.
- 2 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q3 2025.
Based on UBS Group's 13F filing for Q3 2025, filed 13 Nov 2025.